Meconium aspiration syndrome (MAS) is associated with increased risk for perinatal mortality and morbidities. To provide an overview of the advances in our knowledge concerning the obstetric approaches to the prevention of MAS. The evidence of the effectiveness of intrapartum surveillance, amnioinfusion, and delivery room management in the prevention of MAS are reviewed in the present paper. Meconium aspiration syndrome remains one of the most common but challenging conditions for obstetricians and pediatricians. The available evidence did not demonstrate a beneficial effect of either of obstetric strategies in the prevention of MAS.
Introduction
Meconium staining of the amniotic fluid (MSAF) occurs in <5% of preterm, 7 to 22% of term deliveries, increasing to between 23 and 52% of births at >42 weeks. [1] [2] [3] [4] [5] [6] [7] The mechanisms influencing meconium passage are complex, involving hormonal and neuroregulatory functions, chronic hypoxia or reflecting maturation of the fetal gastrointestinal system. [8] [9] [10] [11] MSAF is associated with an increased risk of neonatal morbidity and mortality. Meconium aspiration syndrome (MAS) is the most serious neonatal pathology associated with MSAF. It has been reported to occur in 1.7 to 35.8% of cases complicated with MSAF, and 1 to 3% of liveborn infants. 1, [12] [13] [14] The case fatality rate of MAS has been reported to be high, ranging from 5 to 40%. 1, [13] [14] [15] [16] [17] Approximately one-third of babies with MAS require intubation and mechanical ventilation, and other new therapies such as high frequency ventilation, inhaled nitric oxide and surfactant administration, although the effectiveness of certain of these technologies remain controversial. 2, [17] [18] [19] Serious complications resulting from MAS include pneumothorax, convulsion and death.
Definition of meconium aspiration syndrome Rossi et al. 20 has defined MAS as respiratory distress in the first 4 h after birth with oxygen requirement and chest roentgenogram showing characteristic features of MAS. Recently, Cleary and Wiswell have defined MAS as respiratory distress in an infant born through MSAF, which cannot be otherwise explained. Mild MAS has been defined as requiring <40% oxygen for <48 h, moderate MAS as requiring >40% concentration of oxygen therapy for at least 48 h, and severe MAS if requiring assisted mechanical ventilation, that is, often associated with persistent pulmonary hypertension. 1, 20 They further pointed out that the severity of MAS does not necessarily correspond to the degree of chest radiographic abnormality. MAS is associated with a range of radiographic features including coarse, patchy infiltrates, consolidation, atelectasis, pleural effusions, air leaks, hyperinflation, a wet-lung picture and hypovascularity. 1 In some cases, the chest film may be interpreted as normal. 1 
Pathophysiology and risk factors
The pathophysiology of MAS is complex and remains controversial. Many factors, such as airway obstruction, alveolar or parenchymal inflammation, impaired surfactant production and function and direct toxicity of meconium constituents could be involved in the pathophysiology of the MAS. 1, 21, 22 It has been suggested that the extent of lung destruction is not closely correlated to the quantity of meconium in lung tissue but rather to the degree of hypoxia and acidosis present at delivery. 23 Ghidini and Spong 22 postulated that the pathologic events leading to mild, moderate or severe cases of MAS may be different. Severe MAS may not be in fact causally related to the aspiration of meconium but rather may be caused by other pathologic processes occurring in utero, such as chronic asphyxia, infection or persistent pulmonary hypertension. 22 The hypothesis is in fact supported by the lack of evidence that the severity of MAS directly correlates with the amount of meconium aspirated, the consistency of meconium and the duration of exposure to meconium. 1, 15, 20, 22, 23 It is still unclear whether obstruction of airways because of aspiration of meconium has a pivotal role in the progress of MAS. MAS can occur before delivery, even in the absence of labor, being reported in infants delivered by elective cesarean section. 24 Although the presence of meconium during labor is known to be associated with an increased risk of perinatal morbidity and mortality, most babies have favorable outcomes. Early recognition of infants at the highest risk for the development of MAS could be essential for optimizing the clinical preventive strategies. A vast array of risk factors for the occurrence of MAS have been identified either using unselected obstetrical populations or infants born through MSAF. Those factors are heavy MSAF, nulliparity, postterm delivery, fetal heart rate (FHR) abnormalities during labor, presence of meconium below the vocal cords, cesarean delivery and the low Apgar scores. 13, 14, 20, [25] [26] [27] [28] [29] [30] It has been reported that there is an apparent relationship between maternal ethnicity and risk of MSAF, and the risk of MAS having been observed to be increased in black Americans, Africans and Pacific Islanders.
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Intrapartum fetal monitoring The goal of continuous electronic fetal heart rate monitoring (EFM) is to detect fetal hypoxemia and therefore reduce the risk of adverse neonatal outcomes. However, the effectiveness of this approach to care has been questioned. Randomized trials of EFM, with or without fetal blood gas and acid-base assessment, which were conducted in the unselected obstetrical population, have found no evidence that this approach to care reduces the risk of fetal or neonatal mortality or morbidity. [33] [34] [35] [36] [37] [38] [39] Intrapartum monitoring has been recommended to screen for early signs of fetal hypoxia, a risk factor for MAS. Several authors have noted an increase in the frequency of FHR abnormalities in association with MSAF. 15, 20, 40, 41 It has been reported that, in the presence of MSAF, fetal tachycardia, variable and late decelerations and decreased long-term variability are risk factors for MAS. Certain authors investigated the relationships among abnormal cardiotocograms in labor, MSAF and adverse neonatal outcomes such as low arterial cord blood pH, and low Apgar scores. The authors did not find that the presence of abnormal FHR patterns increased the overall correlation between MSAF and adverse outcome. 7, 42 In contrast, Umstad et al. 43 investigated the predictive value of abnormal FHR patterns in early labor and found that the presence of meconium in the amniotic fluid improved the predictive properties of the test. Amnioinfusion Amnioinfusion (AI), or transcervical infusion of saline into the amniotic cavity, was used first to relieve persistent variable FHR decelerations during labor or to prevent the occurrence of decelerations in presence of oligohydramnios. 44 Results of randomized controlled trials, including a meta-analysis indicate that, in the presence of oligohydramnios, prophylactic intrapartum AI significantly reduces the risk of FHR decelerations and cesarean section. [45] [46] [47] [48] [49] [50] [51] [52] AI has been also proposed as a method to reduce MAS. Potential mechanisms through which AI could act include mechanical cushioning of the umbilical cord, which could correct or prevent recurrent umbilical compressions that lead to fetal acidemia, a condition predisposing to MAS; and dilution of meconium that could reduce its mechanical and inflammatory effects in the pathogenesis of MAS.
To date, more than 15 randomized or quasi-randomized trials of AI for MSAF have been reported, with conflicting results. 53, 54 The methodological quality varied across studies. The largest trial (over 1998 participants) was an international trial performed in 56 centers where EFM and neonatal intubation and suctioning for babies with respiratory difficulty were routinely available. 55 Analysis was by intention to treat. The primary outcome was a composite indicator that included the occurrence of perinatal death and/or moderate or severe MAS. The results indicated that AI showed no effect on the primary outcome (relative risk; RR 1.26, 95% confidence interval; CI 0.82 to 1.95). Furthermore, the frequencies of oropharyngeal suctioning, laryngoscopy or intubation in the delivery room were similar between groups, as were the proportion of babies with meconium visualized below the vocal cords. There were no differences between groups in the occurrence of the combined outcome of perinatal mortality and/or serious morbidity (RR 1.13, 95% CI 0.88 to 1.47). In addition, an analysis that stratified for the presence or absence of variable FHR decelerations before randomization found no effect on the primary outcome either, although the study was underpowered to detect such effects within strata.
We recently conducted a systematic review, integrating the results of the largest trial. 54 Studies were included if they were randomized controlled trials that evaluated the effect of prophylactic AI during labor with MSAF; treatment was randomly allocated (AI versus controls). All included studies were further subjected to a score-based quality assessment for randomized studies that was adapted from the Jadad score. The main analysis was based on the studies that were considered to be of high quality. The meta-analysis included a total of 4030 women, 1999 allocated to AI and 2031 allocated to control. Of these, 3178 women were recruited in clinical settings with standard peripartum surveillance and 852 women were randomized in centers with limited peripartum surveillance, defined as the nonavailability of EFM during labor. The methodological quality varied across studies. Heterogeneity was noted across studies with respect to the AI protocols and the end points evaluated. In the setting of standard peripartum surveillance, the results failed to demonstrate a reduction in the risk of MAS (RR 0.59, 95% CI 0.28 to 1.25), Apgar-5 <7 (RR 0.90, 95% CI 0.58 to 1.41) or caesarean delivery (RR 0.89, 95% CI 0.73 to 1.10). However, in clinical settings with limited peripartum surveillance, AI appeared to reduce the risk of MAS (RR 0.25, 95% CI 0.13 to 0.47). Several findings from this meta-analysis are worthy of comment. Firstly, the observed heterogeneity in the stratum of studies conducted in centers with standard surveillance is largely attributable to our recent large trial. The source of this heterogeneity remains largely unexplained. The most significant finding of the meta-analysis is the apparent discordance in the observed effect of AI on MAS between centers with standard and limited peripartum surveillance. Continuous EFM is a key component in the prevention of asphyxia in patients with MSAF. Therefore, the application of this technology may reduce the contribution of severe asphyxia to the risk of occurrence of MAS. It would appear that in settings where this technology is routinely used, AI confers no additional benefit over EFM in terms of prevention of MAS. However, in settings where continuous EFM is not routinely available, AI may be beneficial for the reduction of MAS. Further studies in such settings are warranted to confirm this hypothesis.
AI may not be without risk. The use of AI has been reported to be associated with adverse events. Complications including uterine overdistension and hypertonia, uterine rupture in association with previous uterine scar, FHR abnormality, umbilical cord prolapse and chorioamnionitis have been reported. [56] [57] [58] [59] Four cases of maternal deaths have been reported associated with the AI. 58, 59 Several authors have reported the occurrence of excessive uterine contractions or unusually rapid labor progress related to AI. In the AI group of Fraser et al.'s 55 trial, 10 women (1.1%) experienced bleeding, and in 63 (6.9%) women, hypertonicity, hydramnios or uterine overdistension was diagnosed during the procedure whereas the incidence of other maternal complications were comparable between AI and control groups.
American College of Obstetricians and Gynecologists has recently published a Committee Opinion that concludes that routine prophylactic AI for the dilution of MSAF should be carried out only in the setting of additional clinical trials. However, they state that AI remains a reasonable approach to the treatment of repetitive variable decelerations, regardless of amniotic fluid meconium status. 60 Delivery room management Routine oropharyngeal suctioning before delivery of the infants' shoulders has long been involved in preventing MAS. The findings of observational studies remain conflicting.
20,26,61 -63 Falciglia et al. 26 compared infants with meconium-stained fluid who underwent 'early' oronasopharyngeal DeLee suctioning with a similar group of infants whose airways were suctioned 'late' (after chest delivery). They found no evidence of benefit of oropharyngeal suctioning in the prevention of MAS. Rossi et al. 20 also reported the similar rates of meconium visualized in the vocal cords despite early oropharyngeal suctioning. In contrast, several authors reported that intrapartum pharyngeal suctioning reduced the severity of MAS and the risk of respiratory distress. [61] [62] [63] They suggested that combined approach of intrapartum oropharyngeal suctioning and endotracheal suctioning was effective in the reduction of MAS.
Vain et al. conducted a multicenter international trial to assess the effectiveness of oropharyngeal and nasopharyngeal suctioning before delivery of the shoulders for the prevention of MAS. They found that the incidence of MAS, need for mechanical ventilation, and neonatal mortality was similar between groups (suction versus no suction). In addition, they found no evidence of a benefit of intrapartum suctioning on the occurrence of MAS, MAS requiring mechanical ventilation, or mortality. 64 Regarding the postdelivery management such as routine endotracheal suctioning and intubation, reports from observational studies suggested that intratracheal suctioning could prevent the occurrence of MAS for meconium-stained neonates and significantly decreased the mortality subsequent to that disorder. [65] [66] [67] Intubation is not without risk and has been associated with hypoxia, bradycardia and laryngeal stridor. [67] [68] [69] [70] Should endotracheal suctioning and intubation be applied universally in infants born through MSAF or selectively reserved for those who are depressed after birth is another topic of controversy. Some investigators suggested that a selective approach may be useful and justified, 6, 8, [71] [72] [73] whereas other suggested that universal intubation and suctioning was the best strategy to prevent potential morbidity and mortality related to meconium staining. 67 Linder et al. 68 suggested that nondepressed meconium-stained infants did not benefit from immediate intratracheal suctioning and such intervention could be harmful. Liu and Harrington conducted a randomized trial to assess if intubation of the low-risk newborn with thin meconium affects the incidence of respiratory symptoms. They were unable to demonstrate the beneficial effect of intubation and intratracheal suctioning in the infant with thin meconium and an otherwise low-risk pregnancy. 74 To address this question, Wiswell et al. 69 conducted a multicenter randomized trial, involving a total of 2094 neonates, to investigate whether intubation and suctioning of apparently vigorous, meconium-stained neonates would reduce the risk of MAS. There were no significant differences between intubation and expectant management groups in the rates of MAS or other respiratory disorders. Moreover, intratracheal suctioning showed no benefit over expectant management even for infants born through the thickest consistency MSAF. They further identified the independent risk factors for the development of MAS using stepwise logistic regression. The results indicated that the use of oropharyngeal suctioning lead to a decreased risk of MAS (8.5% in infants who did not have intrapartum suction versus 2.7% in infants with intrapartum suctioning). The authors concluded that endotracheal intubation and suctioning still be performed in infants born through MSAF, if they are not vigorous, if they need positive pressure ventilation or they develop symptoms of respiratory distress. Furthermore, a recently published meta-analysis of four randomized trials demonstrated no significant benefit of routine endotracheal intubation and suctioning at birth over routine resuscitation including oropharyngeal suction of vigorous, meconium-stained infants born at term. 75 The authors recommended that intubation and suctioning be restricted to depressed newborns, that is, those with a heart rate of <100 beats per min, poor respiratory effort and poor tone.
Conclusion
MAS remains a challenging condition for obstetricians and neonatologists. Despite the decreased risk of MAS and related mortality and morbidity, the available evidence did not demonstrate a beneficial effect of either of obstetric strategies in the prevention of MAS. The suggested apparent disparity in the effect of AI on MAS between centers with standard and limited peripartum surveillance is worthy of attentions for clinicians. Additional well-designed randomized controlled trials in settings of limited peripartum surveillance are required to elucidate the optimal management of MAS in this context. 
